Drug Index

Omalizumab

 
print

Mechanism :

Omalizumab is an IgG monoclonal antibody (recombinant DNA derived) which inhibits IgE binding to the high-affinity IgE receptor on mast cells and basophils


Indication :

• Asthma: Treatment of moderate to severe persistent asthma in adults and patients 6 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

• Chronic idiopathic urticaria: Treatment of chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.


Contraindications :

Severe hypersensitivity reaction to omalizumab or any component of the formulation.


Dosing :

Give SC.

Asthma:

Dose and frequency based on body weight and pre-treatment total IgE serum levels.

Children 6 to <12 years:

Pre-treatment serum IgE ≥30 to 100 units/mL:

20 to 40 kg: 75 mg every 4 weeks.

>40 to 90 kg: 150 mg every 4 weeks.

>90 to 150 kg: 300 mg every 4 weeks.

Pre-treatment serum IgE >100 to 200 units/mL:

20 to 40 kg: 150 mg every 4 weeks.

>40 to 90 kg: 300 mg every 4 weeks.

>90 to 125 kg: 225 mg every 2 weeks.

>125 to 150 kg: 300 mg every 2 weeks.

Pre-treatment serum IgE >200 to 300 units/mL:

20 to 30 kg: 150 mg every 4 weeks.

>30 to 40 kg: 225 mg every 4 weeks.

>40 to 60 kg: 300 mg every 4 weeks.

>60 to 90 kg: 225 every 2 weeks.

>90 to 125 kg: 300 mg every 2 weeks.

>125 to 150 kg: 375 mg every 2 weeks.

Pre-treatment serum IgE >300 to 400 units/mL:

20 to 30 kg: 225 mg every 4 weeks.

>30 to 40 kg: 300 mg every 4 weeks.

>40 kg to 70 kg: 225 mg every 2 weeks.

>70 to 90 kg: 300 mg every 2 weeks.

>90 kg: Do not administer.

Pre-treatment serum IgE >400 to 500 units/mL:

20 to 25 kg: 225 mg every 4 weeks.

>25 to 30 kg: 300 mg every 4 weeks.

>30 to 50 kg: 225 mg every 2 weeks.

>50 to 70 kg: 300 mg every 2 weeks.

>70 to 90 kg: 375 mg every 2 weeks.

>90 kg: Do not administer.

Pre-treatment serum IgE >500 to 600 units/mL:

20 to 30 kg: 300 mg every 4 weeks.

>30 to 40 kg: 225 mg every 2 weeks.

>40 to 60 kg: 300 mg every 2 weeks.

>60 to 70 kg: 375 mg every 2 weeks.

>70 kg: Do not administer.

Pre-treatment serum IgE >600 to 700 units/mL:

20 to 25 kg: 300 mg every 4 weeks.

>25 to 40 kg: 225 mg every 2 weeks.

>40 to 50 kg: 300 mg every 2 weeks.

>50 to 60 kg: 375 mg every 2 weeks.

>60 kg: Do not administer.

Pre-treatment serum IgE >700 to 900 units/mL:

20 to 30 kg: 225 mg every 2 weeks.

>30 to 40 kg: 300 mg every 2 weeks.

>40 to 50 kg: 375 mg every 2 weeks.

>50 kg: Do not administer.

Pre-treatment serum IgE >900 to 1,100 units/mL:

20 to 25 kg: 225 mg every 2 weeks.

>25 to 30 kg: 300 mg every 2 weeks.

>30 to 40 kg: 375 mg every 2 weeks.

>40 kg: Do not administer.

Pre-treatment serum IgE >1,100 to 1,200 units/mL:

20 to 30 kg: 300 mg every 2 weeks.

>30 kg: Do not administer.

Pre-treatment serum IgE >1,200 to 1,300 units/mL:

20 to 25 kg: 300 mg every 2 weeks.

>25 to 30 kg: 375 mg every 2 weeks.

>30 kg: Do not administer.

Chronic idiopathic urticaria:

≥12 years

150 or 300 mg every 4 weeks. Dosing is not dependent on serum IgE or body weight.


Adverse Effect :

Headache, injection site reaction, peripheral edema, pain, dizziness, fatigue, alopecia, urticarial, upper abdominal pain, UTI, fungal infection, arthralgia, otitis media, nasopharyngitis, epistaxis, asthma, cough.


Interaction :

Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine.


07/17/2019 10:34:25 Omalizumab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0